Not happy with the turn of the board over the last couple hundred posts. Thought that kind of rhetoric ad nauseum is why many left the other board. Let's just call it a bad day and get back to topic: CTIX.
Would like to know how most expect the timing to be for the upcoming cohorts. Do they normally take longer to get started as more data has to be studied to analyze the safety issue or do they tend to speed up? I was surprised a trial of this import was held up over the Holidays instead of plowing on thru to the tune of 3 weeks or so of delay. As such, I am now expecting a new cohort only every 6-8 weeks or so at the best.
I still can't believe there is much positive data re: effectiveness from the low dosage levels of the first 2 cohorts (based on results of preclinicals we may get some biomarkers but tumor change is further down the line IMO) or that we have really reached the stage where we can feel at ease as to how later cohorts will react to higher dosages. I do feel very confident things will go well, just saying I am not reading as much into the lack of any bad news to date to be as overwhelming as some seem to believe. So much riding on this for everyone involved that there will be worry (at least for me) until we clear at least the 5th cohort so that would bring us to late Spring in my opinion.
Anybody think we reach efficacy earlier than that?
Let's say DF has solid data that Kevetrin is reducing tumors and patients are tolerating it well by mid May. Even if we haven't hit MTD yet, would the info be enough for them to present the data at ASCO the end of May?
Hate to admit it, but I just came to the realization that BI is not in Jerusalem. I kept wondering how they could get NCI grants if they were not even in the USA. Sure am glad I can laugh at myself.
